Evidence map›Paper›PMID 36669836›Full record

SynthesisBMJ open2023

What variables should inform needle length choice for deltoid intramuscular injection? A systematic review.

Ciléin Kearns, Claire Houghton, Emily Dickinson, Lee Hatter, Pepa Bruce, Srinidhi Krishnamoorthy, Mark Weatherall, Thomas Hills, Marjan Doppen, Seyed Ali Mirjalili and 1 more

Abstract readSystematic Review
In one paragraph

Synthesis in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ciléin KearnsMedical Research Institute of New Zealand, Wellington, New Zealand cilein.kearns@mrinz.ac.nz.ORCID 0000-0003-1254-8287
Claire HoughtonMedical Research Institute of New Zealand, Wellington, New Zealand.
Emily DickinsonMedical Research Institute of New Zealand, Wellington, New Zealand.
Lee HatterMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID 0000-0003-2062-7225
Pepa BruceMedical Research Institute of New Zealand, Wellington, New Zealand.
Srinidhi KrishnamoorthyMedical Research Institute of New Zealand, Wellington, New Zealand.
Mark WeatherallUniversity of Otago Wellington, Wellington, New Zealand.
Thomas HillsMedical Research Institute of New Zealand, Wellington, New Zealand.
Marjan DoppenMedical Research Institute of New Zealand, Wellington, New Zealand.
Seyed Ali MirjaliliUniversity of Auckland, Auckland, New Zealand.
Richard BeasleyMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID 0000-0003-0337-406X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives(1) Assess the distribution of skin-to-deltoid-muscle distance (SDMD) at the deltoid intramuscular (IM) injection site; (2) its relationship with demographic and anthropometric variables and (3) Consider the findings in relation to clinical guidance on IM injection, such as COVID-19 vaccines.

designSystematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. DATA SOURCES: MEDLINE, EMBASE, ClinicalTrials.gov, Cochrane Library, CINAHL and SCOPUS between June and July 2021 with no publication date limit. ELIGIBILITY CRITERIA: Studies reporting measurements of the SDMD in living adults aged 16 years and older, at the deltoid IM injection site, published in English were considered. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers performed each stage of screening, data extraction and quality assessments using the Joanna Briggs Institute Critical Appraisal Checklist for analytical cross sectional studies.

results16 105 papers were identified, of which 11 studies were suitable for review, representing 1414 participants. Heterogeneity in the definition of the deltoid IM injection site, locations measured and methods of measurement precluded meta-analysis. Evidence from ultrasound SDMD measurements demonstrated some patients in all but 'underweight' body mass index (BMI) categories, may require needles longer than 25 mm for successful IM injection. Calliper measurements overestimated SDMD compared with ultrasound. Female sex, higher BMI categories and greater weight in women were associated with greater SDMD.

conclusionsThe reviewed evidence was insufficient to inform definitive needle length 'cut points' for IM injection based on demographic or anthropomorphic variables. Contemporary clinical guidance currently based on this evidence, including the site of injection and choice of needle length, may result in subcutaneous administration in a small proportion of recipients, particularly if obese or of female sex. PROSPERO REGISTRATION NUMBER: CRD42021264625.

Indexed as

COVID-19COVID-19 VaccinesAdultCross-Sectional StudiesFemaleHumansInjections, IntramuscularNeedlesCOVID-19 Vaccinesanatomyinfectious diseasespublic healthultrasound

Identifiers

PMID36669836
PMCPMC9872490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.